Compare Dow Jones Industrial Average ETF (DIA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Merck & Co., Inc. — how do they compare? Dow Jones Industrial Average ETF trades at $515.98 (market cap $45.20B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 7.8× Dow Jones Industrial Average ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Merck & Co., Inc. for 98 Days on average.
| DIA | MRK | |
|---|---|---|
Market Cap | $45.20B | $351.28B |
Volume | 4,095,368 | 7,969,665 |
52-Week High | $542.79 | $156.43 |
52-Week Low | $451.37 | $82.49 |
Typical Hold Time | 104 Days | 98 Days |
Sector | — | Health |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $516.07, up 0.99% with bearish technical signals from moving averages. The ETF maintains dividend distributions with three recent payouts scheduled through October 2026. Market sentiment reflects broader volatility concerns amid economic uncertainty and Fed policy speculation.
The ETF's outlook remains tied to Dow component performance, with technical resistance at $516 limiting near-term upside. Dividend consistency provides income stability, though bearish momentum and market-wide pressures pose headwinds for large-cap value exposure.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
